Helicobacter pylori (H. pylori) is an important major cause of peptic ulcer disease and gastric
malignancies such as mucosa-associated lymphoid tissue lymphoma and gastric …

Helicobacter pylori (H. pylori) infection is highly associated with the occurrence of
gastrointestinal diseases, including gastric inflammation, peptic ulcer, gastric cancer, and …

Helicobacter pylori (H. pylori) is a major human pathogen associated with significant
morbidity and mortality. However, after decades of efforts, treatment of H. pylori remains a …

Triple therapy, consisting of two antibiotics, clarithomycin and amoxicillin or metronidazole in
combination with a proton pump inhibitor (PPI) has become the first-line option for infection …

With the rising prevalence of antimicrobial resistance, the treatment success of standard
triple therapy has recently declined to unacceptable levels (ie, 80% or less) in most …

Helicobacter pylori (H. pylori) is a successful pathogen that can persist in the stomach of an
infected person for their entire life. It provokes chronic gastric inflammation that leads to the …

Many interesting articles have been published from many parts of the world over the last
year assessing different issues around Helicobacter pylori eradication therapy. This article …

Background. None of the currently used anti‐Helicobacter pylori drug regimens cures the
infection 100%, and cure results still vary considerably. The present article reviews the …

Helicobacter pylori infection still represents a major health issue, especially in developing
countries, with an estimate of 4 billion of infected subjects in 2015. The increase of antibiotic …

This paper reviews the literature about first‐line therapies for H. pylori infection in recent
years. First‐line therapies are facing a challenge because of increasing treatment failure …